74. Prolactin secreting pituitary adenoma Clinical trials / Disease details

Clinical trials : 19 / Drugs : 28 - (DrugBank : 10) / Drug target genes : 14 - Drug target pathways : 65

4 trials found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03400865 (ClinicalTrials.gov)	October 25, 2018	8/1/2018	Cabergoline Combined Hydroxychloroquine/Chloroquine to Treat Resistant Prolactinomas	The Effect of Combined Treatment of Cabergoline With Hydroxychloroquine/Chloroquine for Resistant Prolactinomas	Resistance, Disease;Prolactinoma	Drug: HCQ/CQ and CAB combined treatment	Zhebao Wu	Xinqiao Hospital of Chongqing;First Hospital of China Medical University;Beijing Tiantan Hospital;First Affiliated Hospital of Wenzhou Medical University;First Affiliated Hospital of Fujian Medical University;Peking Union Medical College Hospital;Huashan Hospital;Chinese PLA General Hospital	Not yet recruiting	18 Years	70 Years	All	30	N/A	China
2	NCT03457389 (ClinicalTrials.gov)	February 22, 2018	23/1/2018	Comparison of Treatment Outcome of Cabergoline According to Target Prolactin Levels in Patients With Prolactinoma	Comparison of Treatment Outcome of Cabergoline According to Target Prolactin Levels in Patients With Prolactinoma: A Prospective, Randomized, Open Label, Active-controlled, Clinical Trial	Pituitary Adenoma;Prolactinoma;Pituitary Tumor;Recurrence Tumor	Drug: Cabergoline	Seoul National University Hospital	NULL	Recruiting	19 Years	N/A	All	68	N/A	Korea, Republic of
3	NCT01620138 (ClinicalTrials.gov)	March 2010	18/9/2011	Response to Cabergoline and Pasireotide in Non-functioning Pituitary Adenomas and Resistant Prolactinomas	Somatostatin and Dopamine Receptors Expression in Non-functioning Pituitary Adenomas and Resistant Prolactinomas: Correlation With in Vitro and in Vivo Responsiveness to Somatostatin Analogs and Dopamine Agonist	Non-functioning Pituitary Adenomas;Prolactinomas	Drug: Pasireotide;Drug: cabergoline	Universidade Federal do Rio de Janeiro	NULL	Completed	18 Years	N/A	All	21	Phase 2/Phase 3	Brazil
4	NCT00460616 (ClinicalTrials.gov)	January 2007	13/4/2007	Cardiac Valve Complications in Prolactinomas Treated With Cabergoline	Observational Study to Investigate the Prevalence of Cardiac Abnormalities and Valvular Regurgitation in Patients With Prolactinomas Treated Chronically With Cabergoline	Prolactinomas	Drug: Cabergoline	Federico II University	NULL	Completed	18 Years	65 Years	Both	50		Italy